Keywords (1)

Academic
Publications
Clinical Differences Between Solifenacin and Tolterodine

Clinical Differences Between Solifenacin and Tolterodine,10.1007/s11884-010-0075-2,Current Bladder Dysfunction Reports,Anne K. Mongiu,Lori B. Lerner

Clinical Differences Between Solifenacin and Tolterodine  
BibTex | RIS | RefWorks Download
Overactive bladder (OAB) is characterized by involuntary detrusor contractions that result in bothersome urinary symptoms. The estimated US prevalence of OAB is 16% among men and 16.9% among women, comprising some 37.4 million Americans. The mainstay of treatment is medication. Although all drugs have variable degrees of efficacy and tolerability, several have emerged that yield good clinical results with tolerable side effects. This review focuses on two frequently prescribed drugs, solifenacin and tolterodine, and compares their clinical efficacy. A PubMed review was conducted with “solifenacin” and “tolterodine” as search words. Articles that compared the two medications were reviewed for content and number of study participants. Those with the most relevant findings and the highest number of participants were included. Both solifenacin and tolterodine show clinical efficacy for the treatment of OAB. Solifenacin seems to have better results in some series, with similar side effects. Antimuscarinic therapy is effective as OAB treatment. Both solifenacin and tolterodine have good clinical efficacy. However, in head—to-head trials, solifenacin seems to have somewhat better outcomes. Solifenacin, 5 mg, has less reported dry mouth than tolterodine, but at 10 mg, the incidence of dry mouth is similar.
Journal: Current Bladder Dysfunction Reports , vol. 6, no. 1, pp. 1-6, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.